A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to EvaLuate the EffIcacy and Safety of AbeLacimab in High-risk Patients with Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral AntiCoagulation (LILAC-TIMI 76)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 27 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abelacimab (Primary)
Indications Embolism; Stroke; Thrombosis
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms LILAC-TIMI 76
Sponsors Anthos Therapeutics

Most Recent Events

11 Feb 2025 According to an Anthos Therapeutics media release,data from this trials are expected in the second half of 2026.
07 Oct 2024 Planned End Date changed from 1 Mar 2025 to 1 Oct 2026.
07 Oct 2024 Planned primary completion date changed from 1 Jan 2025 to 1 Aug 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight